Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

C.W. Hong, S.K. Libutti, B.J. Wood

Abstract


Radiofrequency ablation (rfa) is a standard treatment for small, unresectable hepatocellular carcinomas (hccs). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.


Keywords


RFA; ablation; hepatocellular carcinoma; doxorubicin; liposomes

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.20.1266






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)